Voxelotor: A Novel Treatment for Sickle Cell Disease

Area of Science:

• Hematology
• Pharmacology
• Genetics

Background:

• Sickle cell disease (SCD) is an inherited blood disorder causing significant morbidity and mortality.
• Current SCD treatments reduce complications but do not address the underlying disease pathophysiology.
• Voxelotor represents a novel therapeutic approach targeting the core mechanisms of SCD.

Purpose of the Study:

• To review the pharmacological properties of voxelotor.
• To evaluate the clinical evidence supporting voxelotor for SCD treatment.
• To determine the optimal place of voxelotor in the therapeutic landscape for SCD.

Main Methods:

• A comprehensive literature search was conducted using PubMed, ClinicalTrials.gov, and other sources.
• Search terms included "GBT440," "sickle cell," and "voxelotor."
• English-language articles, case reports, and Phase 1-3 clinical trials were included and evaluated.

Main Results:

• A Phase 3 trial demonstrated a significant increase in mean hemoglobin levels with voxelotor compared to placebo (1.1 vs -0.1 g/dL, P < 0.001).
• Voxelotor was generally well-tolerated, with common adverse effects including headache, diarrhea, nausea, and arthralgia.
• The drug targets the pathophysiology of SCD, offering a disease-modifying potential.

Conclusions:

• Voxelotor may be considered for patients with SCD experiencing persistent anemia and hemolysis, even with optimal hydroxyurea therapy or intolerance.
• The cost-effectiveness of voxelotor should be carefully considered alongside its benefits.
• Voxelotor shows promise as a safe and effective monotherapy or in combination with hydroxyurea for individuals aged 12 and older with SCD.